Neuroscience
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs
British Journal of Clinical Pharmacology. 2011 Oct 28;
Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F
Abstract
Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine. These drugs provide symptomatic relief but poorly affect the progression of the disease. Drug discovery has been directed, in the last ten years, to develop "disease-modifying drugs" hopefully able to counteract the progression of AD. Because in a chronic, slow progressing pathological process, such as AD, an early start of treatment enhances the chance of success, it is crucial to have biomarkers for early detection of AD-related brain dysfunction, usable before clinical onset. Reliable early biomarkers need therefore to be prospectively tested for predictive accuracy, with specific cutoff values validated in clinical practice. Disease-modifying drugs developed so far include drugs to reduce β amyloid (Aβ) production, drugs to prevent Aβ aggregation, drugs to promote Aβ clearance, drugs targeting tau phosphorylation and assembly, and other approaches. Unfortunately none of these drugs has demonstrated efficacy in phase 3 studies. The failure of clinical trials with disease-modifying drugs rises a number of questions, spanning from methodological flaws to fundamental understanding of AD patho-physiology and biology. Recently, new diagnostic criteria applicable to presymptomatic stages of AD have been published. These new criteria may impact drug development, such that future trials on disease-modifying drugs will include populations susceptible to AD, before clinical onset. Specific problems with completed trials and hopes with ongoing trials are discussed in this review.
PMID: 22035455 [PubMed - as supplied by publisher]
- Upcoming Event:alzheimer's Drug Discovery (jersey City, Nj, 14-15 September)
The 10th international conference on Alzheimer's disease drug discovery takes place next week on the 14th and 15th in Jersey City, NJ. From the conference website: "The 10th International Conference on Alzheimer's Disease Drug Discovery is presented...
- Upcoming Event: Alzheimer Disease (las Vegas, 29-30 Oct 2009)
2nd Conference on Clinical Trials on Alzheimer’s Disease (CTAD) From the conference website: "Dear Colleague, "It is a great pleasure for us to invite you to attend the 2nd conference Clinical Trials on Alzheimer’s Disease (CTAD), which will take...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Drug Development
Becker RE & Greig NH. Alzheimer's disease drug development in 2008 and beyond: Problems and opportunities. Current Alzheimer Research. 2008 Aug; 5(4): 346-357. Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program,...
- Abstract Of The Day: Alzheimer Disease Drug Treatments
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD005593. BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients...
- In The Weeklies: Alzheimer Disease Treatments
The 06 August 2005 issue of the British Medical Journal includes the full-text contents of this paper reviewing the pharmacological treatment of Alzheimer disease:Hanna Kaduszkiewicz, Thomas Zimmermann, Hans-Peter Beck-Bornholdt, & Hendrik van den Bussche....
Neuroscience
Neuropsychology Abstract of the Day: Alzheimer's Disease Pharmacologic Strategies
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs
British Journal of Clinical Pharmacology. 2011 Oct 28;
Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F
Abstract
Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine. These drugs provide symptomatic relief but poorly affect the progression of the disease. Drug discovery has been directed, in the last ten years, to develop "disease-modifying drugs" hopefully able to counteract the progression of AD. Because in a chronic, slow progressing pathological process, such as AD, an early start of treatment enhances the chance of success, it is crucial to have biomarkers for early detection of AD-related brain dysfunction, usable before clinical onset. Reliable early biomarkers need therefore to be prospectively tested for predictive accuracy, with specific cutoff values validated in clinical practice. Disease-modifying drugs developed so far include drugs to reduce β amyloid (Aβ) production, drugs to prevent Aβ aggregation, drugs to promote Aβ clearance, drugs targeting tau phosphorylation and assembly, and other approaches. Unfortunately none of these drugs has demonstrated efficacy in phase 3 studies. The failure of clinical trials with disease-modifying drugs rises a number of questions, spanning from methodological flaws to fundamental understanding of AD patho-physiology and biology. Recently, new diagnostic criteria applicable to presymptomatic stages of AD have been published. These new criteria may impact drug development, such that future trials on disease-modifying drugs will include populations susceptible to AD, before clinical onset. Specific problems with completed trials and hopes with ongoing trials are discussed in this review.
PMID: 22035455 [PubMed - as supplied by publisher]
- Upcoming Event:alzheimer's Drug Discovery (jersey City, Nj, 14-15 September)
The 10th international conference on Alzheimer's disease drug discovery takes place next week on the 14th and 15th in Jersey City, NJ. From the conference website: "The 10th International Conference on Alzheimer's Disease Drug Discovery is presented...
- Upcoming Event: Alzheimer Disease (las Vegas, 29-30 Oct 2009)
2nd Conference on Clinical Trials on Alzheimer’s Disease (CTAD) From the conference website: "Dear Colleague, "It is a great pleasure for us to invite you to attend the 2nd conference Clinical Trials on Alzheimer’s Disease (CTAD), which will take...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Drug Development
Becker RE & Greig NH. Alzheimer's disease drug development in 2008 and beyond: Problems and opportunities. Current Alzheimer Research. 2008 Aug; 5(4): 346-357. Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program,...
- Abstract Of The Day: Alzheimer Disease Drug Treatments
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD005593. BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients...
- In The Weeklies: Alzheimer Disease Treatments
The 06 August 2005 issue of the British Medical Journal includes the full-text contents of this paper reviewing the pharmacological treatment of Alzheimer disease:Hanna Kaduszkiewicz, Thomas Zimmermann, Hans-Peter Beck-Bornholdt, & Hendrik van den Bussche....